PRESCRIBED BIOLOGIC IN CRSwNP
BY ENTs AND ALLERGISTS3
THE ONLY BIOLOGIC FDA-
APPROVED
FOR PATIENTS
AGED 12-17 YEARS
with inadequately controlled CRSwNP1
WITH DUPIXENT, AIM TO BREAK THE
CYCLE OF
RECURRENCE IN CRSwNP1,2:
Sources of type 2 inflammation
- DUPIXENT targets IL‑4 and IL‑13 signaling, two of the key and central drivers of type 2 inflammation and its disease burdens1,4,5,a
aThe mechanism of dupilumab action has
not been definitively established.1
- Addressing sources of type 2 inflammation may help break the cycle of recurrence—a systemic cycle of chronic symptoms, SCS bursts, and sinus surgeries—in CRSwNP6-12
SYMPTOMS
- Rapid results at Day 3 for Loss of Smellb and Day 2 for nasal congestion13,c
Post hoc analysis. Results are descriptive. Definitive conclusions cannot be made.13,14
- Sustained results through
Week 521,2,d-g
Data in adults.1,2,13
CONTROL
- 83% fewer patients required surgery1
- 74% fewer patients required systemic steroids1
76% fewer patients required surgery and/or systemic steroids.1,h Individually, these were not multiplicity-adjusted endpoints.1,2 Data in adults.1
Phase 3 Clinical Trials in Adults: Coprimary Endpoints, LSM difference, DUPIXENT 300 mg Q2W + INCS vs placebo + INCS at Week 241,2
SINUS-24 (DUPIXENT n=143, placebo n=133): NC score: -0.89 (95% CI: -1.07, -0.71). NPS: -2.06 (95% CI: -2.43, -1.69).
SINUS-52 (DUPIXENT n=295, placebo n=153): NC score: -0.87 (95% CI: -1.03, -0.71). NPS: -1.80 (95% CI: -2.10, -1.51).
bLSM difference between DUPIXENT 300 mg Q2W + INCS (n=438) and placebo + INCS (n=286): -0.07 (95% CI: -0.12, -0.02).13,15 Patient-reported outcome.13,14
cLSM difference between DUPIXENT 300 mg Q2W + INCS (n=438) and placebo + INCS (n=286): -0.07 (95% CI: -0.13, -0.01).13,15
dLoS score at Week 24 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): -0.98 (95% CI: -1.15, -0.81) (P<0.0001).2
eNC score at Week 24 in SINUS-52 (coprimary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): -0.87 (95% CI: -1.03, -0.71) (P<0.0001).1,2
fLoS score at Week 52 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -1.10 (95% CI: -1.31, -0.89).1 Analysis was not multiplicity controlled. Results are descriptive.2
gNC score at Week 52 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -0.98 (95% CI: -1.17, -0.79) (P<0.0001).2
hIn SINUS-24 and SINUS-52, DUPIXENT (Day 0: n=438; Week 24: n=376; Week 52: n=100); placebo (Day 0: n=286; Week 24: n=187; Week 52: n=61).1
Loss of Smell (LoS) score (range 0-3): reduced score indicates improvement.1
Nasal congestion/obstruction (NC) score (range 0-3): reduced score indicates improvement.1
Nasal polyp score (NPS) (range 0-4 for each nostril, range 0-8 in total): reduced score indicates improvement.1
INCS, intranasal corticosteroids; LSM, least squares mean; Q2W, once every 2 weeks; SCS, systemic corticosteroid.
Use of DUPIXENT for the CRSwNP indication in patients aged 12-17 years is supported by evidence from studies of DUPIXENT as add-on maintenance treatment in adults with inadequately controlled CRSwNP.1
Multiple Administration Options
Offer your adult and pediatric patients 12 years and
older flexible administration: at home or in office.1
Support can make all the difference for patients. DUPIXENT MyWay is a patient support program that can get them started on DUPIXENT with coverage support, financial assistance for eligible patients, one-on-one nursing support, and more.
Check Formulary Status in
Your Area
See the coverage status for DUPIXENT, prior authorization, and
step edit information by ZIP code.
Contact a Field Representative
Connect with a DUPIXENT Field Representative to get answers to
your product-related questions.